Publicacións en colaboración con investigadores/as de University of Pisa (101)

2024

  1. CLO24-088: Efficacy of Fruquintinib in Less Heavily Pretreated Patients (Pts) With Metastatic Colorectal Cancer (mCRC): Profile-Matched Data From FRESCO and FRESCO-2

    Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25

  2. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

2023

  1. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk

    International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248

  2. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies

    Rheumatology (United Kingdom), Vol. 62, Núm. 1, pp. 243-255

  3. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

    Clinical and experimental rheumatology, Vol. 41, Núm. 3, pp. 543-553

  4. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database

    Cancers, Vol. 15, Núm. 16

  5. Evolving Management Paradigm for Stable Ischemic Heart Disease Patients: JACC Review Topic of the Week

    Journal of the American College of Cardiology, Vol. 81, Núm. 5, pp. 505-514

  6. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    The Lancet, Vol. 402, Núm. 10395, pp. 41-53

  7. Identification of novel genetic loci for risk of multiple myeloma by functional annotation

    Leukemia

  8. Nutritional status and the risk of malnutrition in older adults with chronic kidney disease – implications for low protein intake and nutritional care: A critical review endorsed by ERN-ERA and ESPEN

    Clinical Nutrition, Vol. 42, Núm. 4, pp. 443-457

  9. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

    eClinicalMedicine, Vol. 65

  10. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

  11. Prevalence and comorbidities of Sjogren's syndrome patients in the Community of Madrid: A population-based cross-sectional study

    Joint Bone Spine, Vol. 90, Núm. 4

  12. Revascularization strategies versus optimal medical therapy in chronic coronary syndrome: A network meta-analysis

    International Journal of Cardiology, Vol. 370, pp. 58-64

  13. Sarcopenic obesity research perspectives outlined by the sarcopenic obesity global leadership initiative (SOGLI) – Proceedings from the SOGLI consortium meeting in rome November 2022

    Clinical Nutrition

  14. Utilisation of primary healthcare services by Sjögren's syndrome patients in the Community of Madrid and associated factors: a population-based cross-sectional study

    Clinical and experimental rheumatology, Vol. 41, Núm. 12, pp. 2397-2408

2022

  1. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

    European Journal of Cancer, Vol. 177, pp. 154-163

  2. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS)

    Journal of Allergy and Clinical Immunology, Vol. 149, Núm. 2, pp. 659-670

  3. Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 31, Núm. 9, pp. 1863-1866

  4. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103